We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets closed

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
22.75-3.36 (-12.87%)
At close: 04:00PM EDT
23.10 +0.35 (+1.54%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Performance Outlook
Previous Close26.11
Open26.08
Bid22.71 x 100
Ask22.79 x 100
Day's Range22.50 - 26.44
52 Week Range12.32 - 32.10
Volume1,877,352
Avg. Volume697,401
Market Cap983.842M
Beta (5Y Monthly)-0.40
PE Ratio (TTM)N/A
EPS (TTM)-2.32
Earnings DateApr 29, 2024 - May 03, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 13, 2012
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SAVA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cassava Sciences, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/25/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    8 months agoArgus Research
View more
  • GlobeNewswire

    Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

    An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification. Final Clinical Safety Data for Simufilam Are Expected at the Conclusion of the Phase 3 Program. AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced th

  • Simply Wall St.

    Bullish Cassava Sciences Insiders Loaded Up On US$3.12m Of Stock

    Quite a few insiders have dramatically grown their holdings in Cassava Sciences, Inc. ( NASDAQ:SAVA ) over the past 12...

  • GlobeNewswire

    Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

    AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer’s and Parkison’s Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024. Presentation details Title: Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 T

  • GuruFocus.com

    Cassava Sciences Inc (SAVA) Reports Full-Year 2023 Financial Results

    Key Financials and Corporate Updates Highlighted

  • GlobeNewswire

    Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

    $121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over 555 Study Participants Have Completed Our Phase 3 Studies.Topline Data Readout for Our 52-Week Phase 3 Trial Expected Year-End 2024.Internal Investigation by Outside Counsel Has Found No Evidence to Substantiate Allegations of Research Misconduct by the Company. AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq:

  • InvestorPlace

    Exit Now! 3 Biotech Stocks to Sell in February 2024

    The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges. Moreover, despite forecasts pointing to a potential rebound in 2024, the biotech industry is struggling to adapt post-pandemic. For many biotech firms, securing private funding and launching successful IPOs remains a daunting tas

  • GlobeNewswire

    No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

    ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer’s Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Baseline to Month 24.Oral Simufilam Safe, Well-Tolerated. AUSTIN, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today reported top-line results of a two-year clinical safety study

  • Simply Wall St.

    Cassava Sciences, Inc. (NASDAQ:SAVA) most popular amongst retail investors who own 59% of the shares, institutions hold 31%

    Key Insights Cassava Sciences' significant retail investors ownership suggests that the key decisions are influenced by...

  • Motley Fool

    Is There Any Hope for Cassava Sciences Stock?

    Battered by controversy, this company will need to show real results to prosper.

  • InvestorPlace

    3 Biotech Stocks to Sell in January Before They Crash and Burn

    The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as companies’ performance relies heavily on drug approvals. A major drug approval has the potential to multiply stock price several times, while a failure to reach approval may cause an immediate, sharp decline. For the following reasons, it is important to choose biotech investments carefully. Below are th